Agency / Source: SCHOTT North America

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company - SCHOTT Pharma is celebrating its first anniversary as a legally stand-alone company in the field of pharma drug containment solutions and delivery systems - SCHOTT.com
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company

 

PRZOOM - /newswire/ - Mainz, Rhineland-Palatinate, Germany, 2023/08/01 - SCHOTT Pharma is celebrating its first anniversary as a legally stand-alone company in the field of pharma drug containment solutions and delivery systems - SCHOTT.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Supplying pioneering products for long-term pharma industry trends like mRNA, GLP-1, ready-to-use manufacturing as well as homecare solutions;
• Strategy focusing on high-value solutions is paying off key driver of profitability.

The former pharma division of the SCHOTT Group has continued its profitable growth trajectory by supplying high-value solutions that enable pharma manufacturers to safely store and deliver life-saving drugs. In its first year as a carved-out entity, SCHOTT Pharma has further enhanced its line of products, offering the broadest portfolio in the market and catering to the most important trends in the industry: “From new drug categories that require deep-cold storage and more efficient production set-ups, to a shift from hospital to homecare treatments: Pharma companies around the world continue to trust SCHOTT Pharma to provide the ideal solution,” said Andreas Reisse, CEO of SCHOTT Pharma. On average, more than 25,000 injections per minute are provided to patients worldwide through a SCHOTT Pharma product.

The company builds on a global entrepreneurial success story rooted in innovation and 100-years of manufacturing expertise. With a strong global R&D team and close collaboration with an exclusive network of customers and partners, SCHOTT Pharma is setting new industry standards through innovation. "We continue to stay ahead by following a holistic, systemic approach that is based on science, and puts patients’ needs first," explains Reisse.

This future-oriented mind-set has led to recent developments, including:

• The latest innovation SCHOTT TOPPAC® freeze, which allows pharma companies to market their deep-cold medications directly in prefillable polymer syringes for the first time.
• The development of ready-to-use solutions, where SCHOTT Pharma delivers pre-washed and sterilized products to reduce the supply chain complexities for pharma companies.
• Allowing patients to administer drugs in the comfort of their home by providing fully integrated homecare systems together with device manufacturers, which helps to reduce healthcare costs.
• High-value solutions as a key driver of profitability

As recently reported, the company’s strategy of delivering high-value solutions that cater to long-term trends in the pharma industry continues to be a key driver of profitability: In the first half of the fiscal year 20231, the company generated sales of EUR 449 million, marking a strong 13.2% year-on-year growth. EBITDA increased by 16.6% to EUR 132 million, resulting in an EBITDA margin of 29.4% which was 1 percentage point higher than the same period in 2022. “Our strategy of focusing on high-value solutions is paying off as the share of sales from high-margin, high-value solutions increased significantly to 45%,” commented Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

As a global market leader with a pure-play focus on injectables, SCHOTT Pharma is represented in all major pharma hubs with 16 state-of-the-art production sites in Europe, North and Latin America, as well as Asia. The company produces around 13 billion prefillable glass and polymer syringes, cartridges, vials and ampoules each year. By supplying over 1,800 customers, SCHOTT Pharma is helping to make breakthrough therapies available to patients around the world.

1. The fiscal year 2023 runs from October 2022 to September 2023. The financial results in this press release are unaudited combined financials.

About SCHOTT Pharma

SCHOTT Pharma (schott.com) designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated sales of EUR 821 million in the fiscal year 2022.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: SCHOTT North America

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
SCHOTT Pharma |
Contact: Christina Rettig - SCHOTT.com 
+49 06131664094
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SCHOTT North America securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From SCHOTT North America / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.







 
  ©2005-2024 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today